Fulvestrant 129453-61-8 CAS NO.129453-61-8

Min.Order Quantity:: 100 Metric Ton

Purity:: 98%min

Port:: Qingdao,China

Payment Terms:: L/C,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

129453-61-8
Fulvestrant 129453-61-8 seller in China
Fulvestrant 129453-61-8 factory in China

Quick Details

ProName: Fulvestrant 129453-61-8
CasNo: 129453-61-8
Molecular Formula: C32H47F5O3S
Appearance: white powder/crystal
Application: Used for research and industrial manuf...
DeliveryTime: Within7-10 days after receipt of your ...
PackAge: As customer request
Port: Qingdao,China
ProductionCapacity: 100kg/Month Metric Ton/Day
Purity: 98%min
Storage: Store in a cool,dry place and keep awa...
Transportation: Common products:Sea/Air/Courier Dange...
LimitNum: 100 Metric Ton

Superiority

triumph chemical title

triumph company office picture

triumph company advantage

triumph testing title picture

triumph testing way

welcome to contact us

lorcaserin(856681-05-5)is an orally administered agent and a selective 5-ht2c receptor agonist for the treatment of obesity. it had been approved for marketing in us by fda on 27 june in 2012. in clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

Details

fulvestrant//cas no.:129453-61-8

1.base date

name:fulvestrant

cas no.:129453-61-8

molecular formular:c₃₂h₄₇f₅o₃s

fulvestrant chemical structure:

2. details of fulvestrant

superlist name:fulvestrant

molecular formula:c₃₂h₄₇f₅o₃s

cas no.:129453-61-8

purity:99%

synonyms:fulvestrant;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol

molecular weight:606.77

3.description of fulvestrant

fulvestrant (faslodex, astrazeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer inpostmenopausal women with disease progression following anti-estrogen therapy. it is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.